A password will be e-mailed to you.

The Toxic Relationship Between ALS and Frontotemporal Dementia

Summary: Researchers report the C9ORF72 genetic mutation can lead to toxicity in neurons, causing 10 percent of all ALS cases and 10 percent of FTD cases.

Source: USC.

ALS and frontotemporal dementia (FTD) are two neurodegenerative diseases with a toxic relationship, according to a new USC Stem Cell study published in Nature Medicine.

In the study, Yingxiao TK Shi and Shaoyu Sebastian Lin in the laboratory of Justin Ichida describe how a mutation in a gene, called C9ORF72, leads to toxicity in nerve cells–causing 10 percent of all cases of ALS, and an additional 10 percent of FTD.

To understand how this happens, the researchers extracted blood from ALS patients carrying the C9ORF72 mutation, and reprogrammed these blood cells into the motor nerve cells that degenerate and die in the disease.

They also extracted blood from healthy patients, reprogrammed these blood cells into motor nerve cells, and used gene editing to delete the C9ORF72 gene.

Whether patient-derived or gene-edited, all motor nerve cells with the mutation had reduced amounts of the protein normally made by the C9ORF72 gene. Furthermore, by adding supplemental C9ORF72 protein, the researchers could stop the motor nerve cells from degenerating.

Through a series of experiments, the researchers revealed that the motor nerve cells use C9ORF72 protein to build lysosomes–which are cellular compartments used to engulf and break down toxic proteins and other garbage.

Without enough lysosomes, the cells accumulate two key types of garbage. The first type is a large, toxic protein produced by the mutated C9ORF72 gene itself. The second type is an excessive number of receptors, or molecules that receive signals from a neurotransmitter known as glutamate. These receptors respond to glutamate by causing the motor nerve cell to activate. Too much activation can kill a motor nerve cell–a phenomenon known as “excitotoxicity.”

motor neurons

These are motor nerve cells. NeuroscienceNews.com image is credited to Justin Ichida Lab/USC Stem Cell.

Guided by these discoveries, the Ichida Lab is now using patient-derived motor nerve cells to test thousands of potential drugs–with a focus on those that affect lysosomes.

“By understanding the role of lysosomes in ALS and FTD, we can better target our search for new drugs or therapies to treat these devastating diseases,” said Ichida, an assistant professor of stem cell biology and regenerative medicine at USC, and a New York Stem Cell Foundation-Robertson Investigator.

About this neuroscience research article

Co-authors include Kim A. Staats, Yichen Li, Wen-Hsuan Chang, Shu-Ting Hung, Eric Hendricks, Gabriel Linares, Yaoming Wang, Brent Wilkinson, Louise Menendez, Toru Sugawara, Phillip Woolwine, Mickey Huang, Michael J. Cowan, Brandon Ge, Nicole Koutsodendris, K. Perry Sandor, Jacob Komberg, Valerie Hennes, Marcelo Coba, and Berislav Z. Zlokovic from USC; Esther Y. Son from Stanford University; Xinmei Wen and Davide Trotti from Thomas Jefferson University; Kassandra Kisler and Amy R. Nelson from USC and Thomas Jefferson University; Vamshidhar R. Vangoor, Ketharini Senthilkumar, Leonard H. van den Berg, and R. Jeroen Pasterkamp from the University Medical Center Utrecht in the Netherlands; Tze-Yuan Cheng and Shih-Jong J. Lee from DRVision Technologies; Paul August from Icagen Corporation; Jason A. Chen, Nicholas Wisniewski, Victor Hanson-Smith, T. Grant Belgard, and Alice Zhang from Verge Genomics; and Chris Grunseich and Michael Ward from the National Institute of Neurological Disorders and Stroke.

Ichida and August are co-founders of Acurastem, Inc.

Funding: Seventy-five percent of the research was supported by $6 million of U.S. federal funding from the National Institutes of Health (NIH) (AG039452, AG023084, NS034467, R00NS077435, and R01NS097850) and the Department of Defense (W81XWH-15-1-0187). Twenty-five percent of the work was supported by $2 million from private and non-U.S. sources, including the ALS Foundation Netherlands (TOTALS), Epilepsiefonds (12-08, and 15-05), VICI grant Netherlands Organisation for Scientific Research (NWO), the Donald E. and Delia B. Baxter Foundation, the Tau Consortium, the Frick Foundation for ALS Research, the Muscular Dystrophy Association, the New York Stem Cell Foundation, the Regenerative Medicine Initiative at Keck School of Medicine of USC, the USC Broad Innovation Award, and the Southern California Clinical and Translational Science Institute. Staats received support from a Muscular Dystrophy Association Development Grant, Menendez from an NIH training grant (T32DC009975-04), and Son from a Walter V. and Idun Berry Postdoctoral Fellowship.

Source: Zen Vuong – USC
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com image is credited to Justin Ichida Lab/USC Stem Cell.
Original Research: Abstract in Nature Medicine.
doi:10.1038/nm.4490

Cite This NeuroscienceNews.com Article
USC “The Toxic Relationship Between ALS and Frontotemporal Dementia.” NeuroscienceNews. NeuroscienceNews, 5 February 2018.
<http://neurosciencenews.com/als-ftd-8427/>.
USC (2018, February 5). The Toxic Relationship Between ALS and Frontotemporal Dementia. NeuroscienceNews. Retrieved February 5, 2018 from http://neurosciencenews.com/als-ftd-8427/
USC “The Toxic Relationship Between ALS and Frontotemporal Dementia.” http://neurosciencenews.com/als-ftd-8427/ (accessed February 5, 2018).

Abstract

Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons

An intronic GGGGCC repeat expansion in C9ORF72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), but the pathogenic mechanism of this repeat remains unclear. Using human induced motor neurons (iMNs), we found that repeat-expanded C9ORF72 was haploinsufficient in ALS. We found that C9ORF72 interacted with endosomes and was required for normal vesicle trafficking and lysosomal biogenesis in motor neurons. Repeat expansion reduced C9ORF72 expression, triggering neurodegeneration through two mechanisms: accumulation of glutamate receptors, leading to excitotoxicity, and impaired clearance of neurotoxic dipeptide repeat proteins derived from the repeat expansion. Thus, cooperativity between gain- and loss-of-function mechanisms led to neurodegeneration. Restoring C9ORF72 levels or augmenting its function with constitutively active RAB5 or chemical modulators of RAB5 effectors rescued patient neuron survival and ameliorated neurodegenerative processes in both gain- and loss-of-function C9ORF72 mouse models. Thus, modulating vesicle trafficking was able to rescue neurodegeneration caused by the C9ORF72 repeat expansion. Coupled with rare mutations in ALS2, FIG4, CHMP2B, OPTN and SQSTM1, our results reveal mechanistic convergence on vesicle trafficking in ALS and FTD.

Feel free to share this Neuroscience News.
Join our Newsletter
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam. Your email address will not be sold or shared with anyone else.
No more articles
%d bloggers like this: